Skip to main content
Erschienen in: Endocrine 2/2014

01.11.2014 | Original Article

Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria

verfasst von: Miro Šimun Alebić, Tomislav Bulum, Nataša Stojanović, Lea Duvnjak

Erschienen in: Endocrine | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Polycystic ovary syndrome (PCOS) women are more insulin resistant than general population. Prevalence data on insulin resistance (IR) in PCOS vary depending on population characteristics and methodology used. The objectives of this study were to investigate whether IR in PCOS is exclusively associated with body mass and to assess the prevalence of IR in lean and overweight/obese PCOS. Study included 250 consecutive women who attended a Department of Human Reproduction diagnosed as having PCOS according to the Rotterdam criteria. Control group comprised 500 healthy women referred for male factor infertility evaluation during the same period as the PCOS women. PCOS women (n = 250) were more insulin resistant than controls (n = 500) even after adjustment for age and body mass index (BMI) (P = 0.03). Using logistic regression analysis, BMI ≥25 kg/m2 (OR 6.0; 95 % CI 3.3–11.0), PCOS (OR 2.2; 95 % CI 1.4–3.5) and waist circumference ≥80 cm (OR 2.0; 95 % CI 1.1–3.8) were identified as independent determinants of IR (P < 0.001). IR was more prevalent in overweight/obese controls (n = 100) than in lean PCOS women (n = 150), 31 versus 9.3 %, but less prevalent than in overweight/obese PCOS (n = 100), 31 versus 57 %. The prevalence of IR between lean controls (5 %) and lean PCOS (9.3 %) did not significantly differ. Both PCOS-specific and obesity-related IR independently contribute to IR in PCOS. Using HOMA-IR cutoff value of 3.15 specific for Croatian women in our clinical setting, the assessed prevalence of IR in lean and overweight/obese PCOS women was 9.3 and 57 %, respectively.
Literatur
1.
Zurück zum Zitat R.J. Norman, D. Dewailly, R.S. Legro, T.E. Hickey, Polycystic ovary syndrome. Lancet 370, 685–697 (2007)PubMedCrossRef R.J. Norman, D. Dewailly, R.S. Legro, T.E. Hickey, Polycystic ovary syndrome. Lancet 370, 685–697 (2007)PubMedCrossRef
2.
Zurück zum Zitat W.A. March, V.M. Moore, K.J. Willson, D.I. Phillips, R.J. Norman, M.J. Davies, The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum. Reprod. 25, 544–551 (2010)PubMedCrossRef W.A. March, V.M. Moore, K.J. Willson, D.I. Phillips, R.J. Norman, M.J. Davies, The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum. Reprod. 25, 544–551 (2010)PubMedCrossRef
3.
Zurück zum Zitat B.O. Yildiz, G. Bozdag, Z. Yapici, I. Esinler, H. Yarali, Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. 27, 3067–3073 (2012)PubMedCrossRef B.O. Yildiz, G. Bozdag, Z. Yapici, I. Esinler, H. Yarali, Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. 27, 3067–3073 (2012)PubMedCrossRef
4.
Zurück zum Zitat F. Álvarez-Blasco, J.I. Botella-Carretero, J.L. San Millán, H.F. Escobar-Morreale, Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch. Intern. Med. 166, 2081–2086 (2006)PubMedCrossRef F. Álvarez-Blasco, J.I. Botella-Carretero, J.L. San Millán, H.F. Escobar-Morreale, Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch. Intern. Med. 166, 2081–2086 (2006)PubMedCrossRef
5.
Zurück zum Zitat B.C. Fauser, B.C. Tarlatzis, R.W. Rebar, R.S. Legro, A.H. Balen, R. Lobo et al., Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil. Steril. 97, 28–38 (2012)PubMedCrossRef B.C. Fauser, B.C. Tarlatzis, R.W. Rebar, R.S. Legro, A.H. Balen, R. Lobo et al., Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil. Steril. 97, 28–38 (2012)PubMedCrossRef
6.
Zurück zum Zitat E. Diamanti-Kandarakis, A. Dunaif, Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr. Rev. 33, 981–1030 (2012)PubMedCrossRef E. Diamanti-Kandarakis, A. Dunaif, Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr. Rev. 33, 981–1030 (2012)PubMedCrossRef
7.
Zurück zum Zitat L. Moran, H. Teede, Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum. Reprod. Update 15, 477–488 (2009)PubMedCrossRef L. Moran, H. Teede, Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum. Reprod. Update 15, 477–488 (2009)PubMedCrossRef
8.
Zurück zum Zitat J.F. Ascaso, S. Pardo, J.T. Real, R.I. Lorente, A. Priego, R. Carmena, Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 26, 3320–3325 (2003)PubMedCrossRef J.F. Ascaso, S. Pardo, J.T. Real, R.I. Lorente, A. Priego, R. Carmena, Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 26, 3320–3325 (2003)PubMedCrossRef
9.
Zurück zum Zitat T.M. Wallace, J.C. Levy, D.R. Matthews, Use and abuse of HOMA modeling. Diabetes Care 27, 1487–1495 (2004)PubMedCrossRef T.M. Wallace, J.C. Levy, D.R. Matthews, Use and abuse of HOMA modeling. Diabetes Care 27, 1487–1495 (2004)PubMedCrossRef
10.
Zurück zum Zitat F. Lunger, L. Wildt, B. Seeber, Accurate screening for insulin resistance in PCOS women using fasting insulin concentrations. Gynecol. Endocrinol. 29, 541–544 (2013)PubMedCrossRef F. Lunger, L. Wildt, B. Seeber, Accurate screening for insulin resistance in PCOS women using fasting insulin concentrations. Gynecol. Endocrinol. 29, 541–544 (2013)PubMedCrossRef
11.
Zurück zum Zitat A. Dunaif, K.R. Segal, W. Futterweit, A. Dobrjansky, Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38, 1165–1174 (1989)PubMedCrossRef A. Dunaif, K.R. Segal, W. Futterweit, A. Dobrjansky, Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38, 1165–1174 (1989)PubMedCrossRef
12.
Zurück zum Zitat H.J. Teede, S.K. Hutchison, S. Zoungas, The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol. Metab. 18, 273–279 (2007)PubMedCrossRef H.J. Teede, S.K. Hutchison, S. Zoungas, The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol. Metab. 18, 273–279 (2007)PubMedCrossRef
13.
Zurück zum Zitat The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Fertil. Steril. 81, 19–25 (2004) The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Fertil. Steril. 81, 19–25 (2004)
14.
Zurück zum Zitat R. Hatch, R.L. Rosenfield, M.H. Kim, D. Tredway, Hirsutism: implications, etiology, and management. Am. J. Obstet. Gynecol. 140, 815–830 (1981)PubMed R. Hatch, R.L. Rosenfield, M.H. Kim, D. Tredway, Hirsutism: implications, etiology, and management. Am. J. Obstet. Gynecol. 140, 815–830 (1981)PubMed
15.
Zurück zum Zitat A.H. Balen, J.S.E. Laven, S.L. Tan, D. Dewailly, The ultrasound assessment of the polycystic ovary: international consensus definitions. ASRM/ESHRE consensus meeting on polycystic ovary syndrome. Hum. Reprod. Update 9, 505–514 (2003)PubMedCrossRef A.H. Balen, J.S.E. Laven, S.L. Tan, D. Dewailly, The ultrasound assessment of the polycystic ovary: international consensus definitions. ASRM/ESHRE consensus meeting on polycystic ovary syndrome. Hum. Reprod. Update 9, 505–514 (2003)PubMedCrossRef
16.
Zurück zum Zitat S. Livadas, G. Boutzios, F. Economou, K. Alexandraki, X. Xyrafis, M. Christou et al., The effect of oral micronized progesterone on hormonal and metabolic parameters in anovulatory patients with polycystic ovary syndrome. Fertil. Steril. 94, 242–246 (2010)PubMedCrossRef S. Livadas, G. Boutzios, F. Economou, K. Alexandraki, X. Xyrafis, M. Christou et al., The effect of oral micronized progesterone on hormonal and metabolic parameters in anovulatory patients with polycystic ovary syndrome. Fertil. Steril. 94, 242–246 (2010)PubMedCrossRef
17.
Zurück zum Zitat D. Matthews, J. Hosker, A. Rudenski, B. Naylor, D. Treacher, R. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28, 12–19 (1985)CrossRef D. Matthews, J. Hosker, A. Rudenski, B. Naylor, D. Treacher, R. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28, 12–19 (1985)CrossRef
18.
Zurück zum Zitat R.S. Legro, A.R. Kunselman, W.C. Dodson, A. Dunaif, Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84, 165–169 (1999)PubMed R.S. Legro, A.R. Kunselman, W.C. Dodson, A. Dunaif, Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84, 165–169 (1999)PubMed
19.
Zurück zum Zitat D.A. Ehrmann, R.B. Barnes, R.L. Rosenfield, M.K. Cavaghan, J. Imperial, Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22, 141–146 (1999)PubMedCrossRef D.A. Ehrmann, R.B. Barnes, R.L. Rosenfield, M.K. Cavaghan, J. Imperial, Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22, 141–146 (1999)PubMedCrossRef
20.
Zurück zum Zitat L.J. Moran, M.L. Misso, R.A. Wild, R.J. Norman, Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 16, 347–363 (2010)PubMedCrossRef L.J. Moran, M.L. Misso, R.A. Wild, R.J. Norman, Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 16, 347–363 (2010)PubMedCrossRef
21.
Zurück zum Zitat A.J. Karter, E.J. Mayer-Davis, J.V. Selby, R.B. D’Agostino Jr, S.M. Haffner, P. Sholinsky et al., Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women. The Insulin Resistance and Atherosclerosis Study. Diabetes 45, 1547–1555 (1996)PubMedCrossRef A.J. Karter, E.J. Mayer-Davis, J.V. Selby, R.B. D’Agostino Jr, S.M. Haffner, P. Sholinsky et al., Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women. The Insulin Resistance and Atherosclerosis Study. Diabetes 45, 1547–1555 (1996)PubMedCrossRef
22.
Zurück zum Zitat J. Lord, R. Thomas, B. Fox, U. Acharya, T. Wilkin, The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 113, 1203–1209 (2006)PubMedCrossRef J. Lord, R. Thomas, B. Fox, U. Acharya, T. Wilkin, The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 113, 1203–1209 (2006)PubMedCrossRef
23.
Zurück zum Zitat N.K. Stepto, S. Cassar, A.E. Joham, S.K. Hutchison, C.L. Harrison, R.F. Goldstein et al., Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum. Reprod. 28, 777–784 (2013)PubMedCrossRef N.K. Stepto, S. Cassar, A.E. Joham, S.K. Hutchison, C.L. Harrison, R.F. Goldstein et al., Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum. Reprod. 28, 777–784 (2013)PubMedCrossRef
24.
Zurück zum Zitat K. Fišter, I. Kolčić, S.M. Milanović, J. Kern, The prevalence of overweight, obesity and central obesity in six regions of Croatia: results from the Croatian Adult Health Survey. Coll. Antropol. 33, 25–29 (2009)PubMed K. Fišter, I. Kolčić, S.M. Milanović, J. Kern, The prevalence of overweight, obesity and central obesity in six regions of Croatia: results from the Croatian Adult Health Survey. Coll. Antropol. 33, 25–29 (2009)PubMed
25.
Zurück zum Zitat S. Franks, When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome? Clin. Endocrinol. (Oxf) 74, 148–151 (2011)CrossRef S. Franks, When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome? Clin. Endocrinol. (Oxf) 74, 148–151 (2011)CrossRef
26.
Zurück zum Zitat P.R. Kezele, E.E. Nilsson, M.K. Skinner, Insulin but not insulin-like growth factor-1 promotes the primordial to primary follicle transition. Mol. Cell. Endocrinol. 192, 37–43 (2002)PubMedCrossRef P.R. Kezele, E.E. Nilsson, M.K. Skinner, Insulin but not insulin-like growth factor-1 promotes the primordial to primary follicle transition. Mol. Cell. Endocrinol. 192, 37–43 (2002)PubMedCrossRef
27.
Zurück zum Zitat P. Monget, C. Bondy, Importance of the IGF system in early folliculogenesis. Mol. Cell. Endocrinol. 163, 89–93 (2000)PubMedCrossRef P. Monget, C. Bondy, Importance of the IGF system in early folliculogenesis. Mol. Cell. Endocrinol. 163, 89–93 (2000)PubMedCrossRef
28.
Zurück zum Zitat A.M. Fulghesu, P. Villa, V. Pavone, M. Guido, R. Apa, A. Caruso et al., The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82, 644–648 (1997)PubMedCrossRef A.M. Fulghesu, P. Villa, V. Pavone, M. Guido, R. Apa, A. Caruso et al., The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82, 644–648 (1997)PubMedCrossRef
29.
Zurück zum Zitat P.O. Dale, T. Tanbo, E. Haug, T. Abyholm, The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome. Hum. Reprod. 13, 567–570 (1998)PubMedCrossRef P.O. Dale, T. Tanbo, E. Haug, T. Abyholm, The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome. Hum. Reprod. 13, 567–570 (1998)PubMedCrossRef
30.
Zurück zum Zitat D.P. Baldani, L. Škrgatić, M.S. Goldstajn, H. Vrčić, T. Čanić, M. Strelec, Clinical, hormonal and metabolic characteristics of polycystic ovary syndrome among obese and nonobese women in the Croatian population. Coll. Antropol. 37, 465–470 (2013)PubMed D.P. Baldani, L. Škrgatić, M.S. Goldstajn, H. Vrčić, T. Čanić, M. Strelec, Clinical, hormonal and metabolic characteristics of polycystic ovary syndrome among obese and nonobese women in the Croatian population. Coll. Antropol. 37, 465–470 (2013)PubMed
31.
Zurück zum Zitat F.H. Safar, O.A. Mojiminiyi, H.M. Al-Rumaih, M.F. Diejomaoh, Computational methods are significant determinants of the associations and definitions of insulin resistance using the homeostasis model assessment in women of reproductive age. Clin. Chem. 57, 279–285 (2011)PubMedCrossRef F.H. Safar, O.A. Mojiminiyi, H.M. Al-Rumaih, M.F. Diejomaoh, Computational methods are significant determinants of the associations and definitions of insulin resistance using the homeostasis model assessment in women of reproductive age. Clin. Chem. 57, 279–285 (2011)PubMedCrossRef
32.
Zurück zum Zitat C.M. DeUgarte, A.A. Bartolucci, R. Azziz, Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril. 83, 1454–1460 (2005)PubMedCrossRef C.M. DeUgarte, A.A. Bartolucci, R. Azziz, Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril. 83, 1454–1460 (2005)PubMedCrossRef
33.
Zurück zum Zitat T.A. Buchanan, R.M. Watanabe, A.H. Xiang, Limitations in surrogate measures of insulin resistance. J. Clin. Endocrinol. Metab. 95, 4874–4876 (2010)PubMedCrossRefPubMedCentral T.A. Buchanan, R.M. Watanabe, A.H. Xiang, Limitations in surrogate measures of insulin resistance. J. Clin. Endocrinol. Metab. 95, 4874–4876 (2010)PubMedCrossRefPubMedCentral
Metadaten
Titel
Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria
verfasst von
Miro Šimun Alebić
Tomislav Bulum
Nataša Stojanović
Lea Duvnjak
Publikationsdatum
01.11.2014
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2014
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0182-5

Weitere Artikel der Ausgabe 2/2014

Endocrine 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.